Last updated: April 16, 2024
Sponsor: Stanford University
Overall Status: Active - Recruiting
Phase
2
Condition
Migraine (Pediatric)
Pain
Trigeminal Neuralgia
Treatment
Exparel (Bupivacaine Liposome)
Saline
Clinical Study ID
NCT04930887
60832
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with a chief complaint of craniofacial pain (migraine, cluster headache,trigeminal autonomic cephalgia, sphenopalatine ganglioneuraligia, paroxysmalhemicrania) who has Stanford Pain & ENT clinic visit
Exclusion
Exclusion Criteria:
- age <18 or >80
- pregnant women
- economically disadvantaged (not able to afford clinic visits/treatments)
- decisionally impaired (unable to obtain informed consent)
- has allergy to bupivacaine
- unable or unwilling to participate plans to participate in another clinical study atany time during this study
Study Design
Total Participants: 15
Treatment Group(s): 2
Primary Treatment: Exparel (Bupivacaine Liposome)
Phase: 2
Study Start date:
February 01, 2023
Estimated Completion Date:
June 30, 2030
Connect with a study center
Peter H Hwang
Stanford, California 94304
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.